Top

Published in:

01-05-2008 | Review

The role of cyclooxygenase-2 in breast cancer: review

Authors: Gurpreet Singh-Ranger, Mohamed Salhab, Kefah Mokbel

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Abstract

There is a growing body of evidence that COX-2 expression s a fundamental step in breast cancer pathogenesis acting through prostaglandin-dependent and independent mechanisms. Epidemiological studies suggest that NSAIDs confer a moderate degree of benefit against breast cancer. However further work is required to establish how this enzyme system can be best manipulated for therapeutic benefit.

Sasco AJ (2003) Breast cancer and the environment. Horm Res 60(Suppl 3):50PubMed

Picot D, Loll PJ, Garavito RM (1994) The X-Ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367(6460):243–249PubMed

Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC (1999) Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 31(5):551–557PubMed

Smith WL, Garavito M, Dewitt DL (1996) Prostaglandin endoperoxide-H synthases-1 and -2. J Biol Chem 271(52):33157–33160PubMed

Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclooxygenase-2 gene. Biochem J 302(3):723–1127PubMed

Kujubu DA, Herschman HR (1992) Dexamethasone inhibits mitogen induction of the TS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 267(12):7991–7994PubMed

Herschman HR (1996) Prostaglandin synthase-2. Biochim Biophys Acta 1299(1):125–140PubMed

Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclooxygenase-2 gene. Biochem J 302(3):723–727PubMed

Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurones: regulation by synaptic activity and glucocorticoids. Neuron 11(4):371–386PubMed

10.

Simmons DL, Xie W, Chipman JG, Evett GE (1991) Multiple cyclooxygenases: cloning of a mitogen-inducible form. In: Bailey JM (ed) Prostaglandins, leukotrienes, lipoxins and PAF. Plenum Press, New York, pp67–88

11.

Walenga RW, Kester M, Coroneos E, Butcher S, Dwivedi R, Statt C (1996) Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro. Prostaglandins 52(5):341–359PubMed

12.

Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94(6):2504–2510PubMed

13.

Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL (1998) Subcellular localisation of prostaglandin endoperoxidase H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 273(16):9886–9893PubMed

14.

Fitzpatrick FA, Soberman R (2001) Regulated formation of eicosanoids. J Clin Invest 107(11):1347–1351PubMed

15.

Murakami M, Naraba H, Tanioka T, Semmyo N, Nkatari Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostalglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275(42):32783–32792PubMed

16.

Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275(42):32775–32782PubMed

17.

Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czemiak PM (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase-2. Nature 378(6555):406–409PubMed

18.

Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK (1997) Multiple female reproductive failures in cyclooxygenase-2 deficient mice. Cell 91(2):197–208PubMed

19.

Davis BJ, Lennard DE, Lee CA, Tiano HF, Morham SG, Wetsel WC, Langenbach R (1999) Anovulation in cyclooxygenase-2 deficient mice is restored by prostaglandin E2 and interleukin-1 beta. Endocrinology 140(6):2685–2695PubMed

20.

Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA (1995) Prostaglandin synthase-2 gene disruption causes severe renal pathology in the mouse. Cell 83(3):473–482PubMed

21.

Loftin CD, Trivedi DR, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM (2001) Failure of ductus arteriosus closure and remodelling in neonatal mice deficient in cyclooxygenase-1 and -2. Proc Natl Acad Sci USA 98(3):1059–1064PubMed

22.

Rocca B, Spain LM, Pure E, langenbach R, Patrono C, Fitzgerald GA (1999) Distinct roles of prostaglandin H synthases-1 and -2 in T-cell development. J Clin Invest 103(10):1469–1477PubMed

23.

Ohki S, Ogino N, Yamamoto S, Hayaishi O (1979) Prostaglandin hydrperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 254(3):829–836PubMed

24.

Munroe DG, Wang EY, MacIntyre JP, Tam SS, Lee DH, Taylor GR, Zhou L, Plante RK, Kazami SM, Bauerle PA (1995) Novel intracellular signalling function of prostaglandin H synthase-1 in NF-kappa β activation. J Inflamm 45(4):260–268PubMed

25.

Josephy PD, Eling TE, Mason RP (1983) Co-oxidation of benzidine by prostaglandin synthase and comparison with the action of horseradish peroxidase. J Biol Chem 258(9):5561–5569PubMed

26.

Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90(6):455–460PubMed

27.

Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT (2000) Cyclooxygenase-2 is expressed in human pulmonary, colonic and mammary tumours. Cancer 89(12):2637–2645PubMed

28.

Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635PubMed

29.

Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681PubMed

30.

Boland GP, Butt IP, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90:423–429PubMed

31.

Kelly LM, Hill ADK, Kennedy S, Connolly EM, Ramanath R, Teh S, Dijkstra B, Purcell R, McDermott EW, O’Higgins N (2002) Lack of prognostic effect of COX-2 expression in primary breast cancer on short term follow-up. Eur J Surg Oncol 29:707–710

32.

Singh Ranger G, Thomas V, Jewell A, Mokbel K (2004) Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 24(4):2349–2351

33.

Kirkpatrick K, Ogunkolade W, Bustin S, Jenkins P, Ghilchik M, Mokbel K (2001) The mRNA expression of cyclooxygenase-2 and vascular endothelial growth factor in human breast cancer. Breast Cancer Res Treat 69(3):373

34.

Watanabe O, Shimizu T, Imamura H, Kinoshita J, Utada Y, Okabe T, Kimura K, Hirano A, Yoshimatsu K, Aiba M, Ogawa K (2003) Expression of cyclooxygenase-2 in malignant and benign breast tumours. Anticancer Res 23(4):3215–3221PubMed

35.

Yoshimura N, Sano H, Okamoto M, Akioka K, Ushogome H, Kadotani Y, Yoshimura R, Nobori S, Higuchi A, Ohmori Y, Nakamura K (2003) Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg Today 33:805–811PubMed

36.

Zhao XQ, Pang D, Xue YW (2003) Expression of the cyclooxygenase-2 gene in human breast carcinoma. Zhongua Wai Ke Za Zhi 41(6):427–429

37.

Guo GL, Yao ZX, Wu J (2003) The clinical significance of expression of cyclooxygenase-2 gene in breast cancer. Zhongua Yi Xue Za Zhi 83(19):1661–1664

38.

Singh Ranger G, Kirkpatrick KL, Clark GM, Mokbel K (2003) Cyclooxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. Curr Med Res Opin 19(2):131–134PubMed

39.

Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T (1994) Structure of the human cyclooxygenase-2 gene. Biochem J 302(3):723–727PubMed

40.

Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takedo O, Takahashi E, Tanabe T (1994) Characterisation of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 221:889–897PubMed

41.

Chen C-Y, Shyu A-B (1995) AU-rich elements; characterisation and importance in mRNA degradation. Trends Biochem Sci 20:465–470PubMed

42.

Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T (1994) Induction of cyclooxygenase-2 by interleukin 1-alpha. Evidence for post-transcriptional regulation. J Biol Chem 269:11769–11775PubMed

43.

Srivasta SK, Tetsuka T, Daphna-Iken D, Morrison AR (1994) IL 1 beta stabilises COX II mRNA in renal mesangial cells; role of 3′ untranslated region. Am J Physiol 36:F504–F508

44.

Evett GE, Xie W, Chipman JG, Robertson DL, Simmons DL, Prostaglandin GH (1993) Synthase isoenyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens and oncogenes. Arch Biochem Biophys 306:169–177PubMed

45.

Ristimaki A, Narko K, Hla T (1996) Downregulation of cytokine-induced cyclooxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 318(1):325–331PubMed

46.

Sorlie T, Perou CM, Tibshirani R (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS USA 98:10869–10874PubMed

47.

Brueggemeier RW, Richards JA, Petrel TA (2003) Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol 86:501–507PubMed

48.

Read DL, Greene GL, Katzenellenbogen BS (1989) Regulation of estrogen receptor messenger ribonulcelic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol Endocrinol 3(2):295–304PubMed

49.

Katzenellenbogen BS, Norman MJ (1990) Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I serum, and estrogen. Endocrinology 126(2):891–898PubMedCrossRef

50.

Cho H, Aronica SM, Katzenellenbogen BS (1994) Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3′, 5′-Monophosphate, Estradiol, Insulin-like growth factor-I serum, and serum factors. Endocrinology 134(2):658–664PubMed

51.

Vienonen A, Syvala H, Miettinen S, Tuohimaa P, Ylikomi T (2002) Expression of progesterone receptor isoforms A and B is differentially regulated by estrogen in different breast cancer cell lines. J Steroid Biochem Mol Biol 80:307–313PubMed

52.

Salhab M, Singh Ranger G, Mokbel R, Jouhra F, Jiang WG, Mokbel K (2007) Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer (in press)

53.

Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K (2000) Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo [4,5,6] pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91(9):886–892PubMed

54.

Howe LR, Crawford HC, Subbaramaiah K, Haassell JA, Dannenberg AJ, Brown AMC (2001) PEA-3 is upregulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 276(23):20108–20115PubMed

55.

Liu CH, Chang SH, narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21):18563–18569PubMed

56.

Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in APC delta 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 87(5):803–809PubMed

57.

Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman L (2003) Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 63:2347–2350PubMed

58.

Tan KB, Yong WP, Putti TC (2004) Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 44(1):24–28PubMed

59.

Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C (2005) COX-2 expression in DCIS: correlation with VEGF, HER2/neu, prognostic molecular markers and clinicopathological features. Histopathology 46:561–568PubMed

60.

Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8(2):97–114PubMed

61.

Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ (1996) Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56(19):4424–4429PubMed

62.

Sheng H, Williams CS, Shao J, Liang P, Dubois RN, Beauchamp RD (1998) Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of the mitogen-activated protein kinase pathway. J Biol Chem 273(34):22120–22127PubMed

63.

Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R (1999) Regulation of the cyclooxygenase-2 pathway by the HER-2 receptor. Oncogene 18(2):305–314PubMed

64.

Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ (1997) Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 57(14):2890–2895PubMed

65.

Xie W, Herschmann HR (1995) v-src induces prostaglandin synthase-2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 270(46):27622–27628PubMed

66.

Xie W, Herschmann HR (1996) Transcriptional regulation of prostaglandin synthase-2 gene expression by platelet derived growth factor and serum. J Biol Chem 271(49):31742–31748PubMed

67.

Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ (1999) Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274(16):10911–10915PubMed

68.

Nolan RD, Danilowicz RM, Eling TE (1988) Role of arachidonic acid metabolism in the mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor. Mol Pharmacol 33(6):650–656PubMed

69.

Goin M, Pignataro O, Jimenez de Asua L (1993) Early cell cycle diacyglycerol (DAG) content and protein kinase C (PKC) activity enhancement potentiates prostaglandin F2 alpha (PGF2 alpha) induced mitogenesis in Swiss 3T3 cells. FEBS Lett 316(1):68–72PubMed

70.

Bandyopadhyay GK, Imagawa W, Wallace D, Nandi S (1987) Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor. J Biol Chem 262(6):2750–2756PubMed

71.

Huang M, Sharma S, Mao JT, Dubinett SM (1996) Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein synthesis. J Immunol 157(12):5512–5520PubMed

72.

Stolina M, Sharma S, Zhu L, Dubinett SM (2000) Lung cancer cyclooxygenase-2 dependent inhibition of dendritic cell maturation and function. Proc Am Assoc Cancer Res 41:619

73.

Rolland PH, Martin PM, Jacquerier J, Roland AM, Toga M (1980) Prostaglandin production in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64(5):1061–1070PubMed

74.

James VHT, Reed MJ (1980) Steroid hormones and human cancer. Prog Cancer Res Ther 14:471–487

75.

Zhao Y, Agarwal VR, Mendelsohn CR, Simpson ER (1996) Oestrogen biosynthesis proximal to a breast tumour is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137(12):5739–5742PubMed

76.

Zhao Y, Agarwal VR, Mendelsohn CR, Simpson ER (1997) Transcriptional regulation of CYP19 (aromatase) gene expression in adipose stromal cells in primary culture. J Steroid Biochem Mol Biol 61(3–6):203–210PubMed

77.

Yamamoto K, Arakawa T, Veda N, Yamamoto S (1995) Transcriptional roles of nuclear factor-interleukin-6 in the tumour necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270(52):31315–31320PubMed

78.

Prescott SM, Fitzpatrick FA (2000) Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470(2):M69–M78PubMed

79.

Wiese FW, Thompson PA, Kadlubar FF (2001) Carcinogen substrate specificity of human cyclooxygenase-1 and cyclooxygenase-2. Carcinogenesis 22(1):5–10PubMed

80.

Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis-induced by colon cancer cells. Cell 93(5):705–716PubMed

81.

Gately S (2001) The contributions of cyclooxygenase-2 to tumour angiogenesis. Cancer Metastasis Rev 19(1–2):19–27

82.

Kirkpatrick K, Ogunkolade W, Bustin S, Jenkins P, Ghilchik M, Mokbel K (2001) The mRNA expression of cyclooxygenase-2 and vascualr endothelial growth factor in human breast cancer. Breast Cancer Res Treat 69(3):373

83.

Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11):1589–1594PubMedCrossRef

84.

Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52(20):5575–5589PubMed

85.

Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T (1999) Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett 460(1):145–148PubMed

86.

Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, Jang Y, Cho SH, Kim HK (2000) Co-expression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 41(1):82–88PubMed

87.

Iawata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y (1996) Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87(6):602–611

88.

Friedman GD, Ury HK (1980) Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 65(4):723–733PubMed

89.

Paganini-Hill A, Cho A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 299(6710):1247–1250CrossRef

90.

Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 83(5):355–358PubMed

91.

Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW (1993) Aspirin use and risk of fatal cancer. Cancer Res 53(6):1322–1327PubMed

92.

Harris RE, Kasbari S, Farrar WB (1999) Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6(1):71–73PubMed

93.

Schreinmachers DM, Everson RB (1994) Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5(2):138–146CrossRef

94.

Sharpe CR, Collett JP, McNutt M, Belzille E, Bowin JF, Hanley JA (2000) Nested case-control study of the effects of nonsteroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83(1):112–120PubMed

95.

Cotterchio M, Krieger N, Sloan M, Steinegart A (2001) Non-steroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10(11):1213–1217PubMed

96.

Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a metaanalysis. Br J Cancer 84(9):1188–1192PubMed

97.

Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1):47–55PubMed

98.

Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G (2001) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119(Suppl 1):39S–63SPubMed

99.

Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res 60(8):2101–2103PubMed

100.

Suzui N, Sugie S, Rahman KM, Ohnishi M, Yoshimi N, Wakabayashi K, Mori H (1997) Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenyl-imidazole [4,5-b] pyridine-induced mammary carcinogenesis in rats. Jpn J Cancer Res 88(8):705–711PubMed

101.

Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000) Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor in a rat mammary tumour model. Oncol Rep 7(6):1377–1381PubMed

102.

Chow LW, Wong JL, Toi M (2003) Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 86(3–5):443–447PubMed

103.

Parret ML, Harris RL, Joarder FS, Ross MS, Clausen KP, Robertson FM (1997) Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10:503–508

104.

Kirtikara K, Morham SG, Raghow R, Laulederkind SJF, Kanekura T, Goorha S, Ballou LR (1998) Compensatory prostaglandin E2 biosynthesis in cyclooxygenase-1 or cyclooxygenase-2 null cells. J Exp Med 187(4):517–523PubMed

105.

Juni P, Rutjes AWS, Dieppe PA (2002) Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 324:1287–1288PubMed

106.

Levesque LE, Brophy JM, Zhang B (2005) The risk of myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 142(7):481–489PubMed

107.

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Adenoma prevention with celecoxib (APC) study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071–1080PubMed

Title: The role of cyclooxygenase-2 in breast cancer: review
Authors: Gurpreet Singh-Ranger
Mohamed Salhab
Kefah Mokbel
Publication date: 01-05-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9641-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study

Core wash cytology of breast lesions by ultrasonographically guided core needle biopsy

Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells

A plant oxylipin, 12-oxo-phytodienoic acid, inhibits proliferation of human breast cancer cells by targeting cyclin D1

Spindle cell lesions of the breast—the pathologic differential diagnosis

Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone

Keynote webinar | Spotlight on antibody–drug conjugates in cancer